171 related articles for article (PubMed ID: 36822323)
21. Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.
Pagliara MM; Tagliaferri L; Azario L; Lenkowicz J; Lanza A; Autorino R; Caputo CG; Gambacorta MA; Valentini V; Blasi MA
Brachytherapy; 2018; 17(2):432-438. PubMed ID: 29275868
[TBL] [Abstract][Full Text] [Related]
22. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
Perri P; Fiorica F; D'Angelo S; Lamberti G; Parmeggiani F; Martini A; Carpenteri F; Colosimo C; Micucci M; Perazzini L; De Gugliemo E; Berretta M; Sebastiani A; Cartei F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1919-24. PubMed ID: 23242717
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of visual function in posterior uveal melanoma patients treated with I125 episcleral brachytherapy in a Spanish referral Ocular Oncology Unit.
Vicente N; Saornil MA; Almaraz A; Muñoz-Moreno MF
Arq Bras Oftalmol; 2021; 84(4):330-338. PubMed ID: 33567036
[TBL] [Abstract][Full Text] [Related]
24. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
[TBL] [Abstract][Full Text] [Related]
26. Plaque brachytherapy for uveal melanoma: a vision prognostication model.
Khan N; Khan MK; Bena J; Macklis R; Singh AD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e285-90. PubMed ID: 22658514
[TBL] [Abstract][Full Text] [Related]
27. Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma.
Sener EC; Kiratli H; Gedik S; Sanac AS
J AAPOS; 2004 Feb; 8(1):38-45. PubMed ID: 14970798
[TBL] [Abstract][Full Text] [Related]
28. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool.
Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD
JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414
[TBL] [Abstract][Full Text] [Related]
29. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
30.
Jiang P; Purtskhvanidze K; Kandzia G; Neumann D; Luetzen U; Siebert FA; Roider J; Dunst J
Radiat Oncol; 2020 Jul; 15(1):183. PubMed ID: 32727533
[TBL] [Abstract][Full Text] [Related]
31. Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy.
Demirci H; Saponara F; Khan A; Niziol LM; Lee C; Hayman JA; Comer G; Musch DC
Middle East Afr J Ophthalmol; 2015; 22(1):103-7. PubMed ID: 25624683
[TBL] [Abstract][Full Text] [Related]
32. Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose.
Espensen CA; Jensen PK; Fog LS; Appelt AL; Klemp K; Fledelius HC; Specht L; Kiilgaard JF
Br J Ophthalmol; 2017 Sep; 101(9):1206-1210. PubMed ID: 28159770
[TBL] [Abstract][Full Text] [Related]
33. Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management.
Bellerive C; Aziz HA; Bena J; Wilkinson A; Suh JH; Plesec T; Singh AD
Am J Ophthalmol; 2017 May; 177():9-16. PubMed ID: 28163118
[TBL] [Abstract][Full Text] [Related]
34. NEW ULTRA-WIDE-FIELD ANGIOGRAPHIC GRADING SCHEME FOR RADIATION RETINOPATHY AFTER IODINE-125 BRACHYTHERAPY FOR UVEAL MELANOMA.
McCannel TA; Kim E; Kamrava M; Lamb J; Caprioli J; Yang D; McCannel CA
Retina; 2018 Dec; 38(12):2415-2421. PubMed ID: 29016456
[TBL] [Abstract][Full Text] [Related]
35. Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.
Char DH; Kroll S; Phillips TL; Quivey JM
Ophthalmology; 2002 Oct; 109(10):1850-4. PubMed ID: 12359605
[TBL] [Abstract][Full Text] [Related]
36. Scleral patch grafts in the management of uveal and ocular surface tumors.
Barman M; Finger PT; Milman T
Ophthalmology; 2012 Dec; 119(12):2631-6. PubMed ID: 22858126
[TBL] [Abstract][Full Text] [Related]
37. Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells.
Corrêa ZM; Augsburger JJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):556-9. PubMed ID: 24408979
[TBL] [Abstract][Full Text] [Related]
38. Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series.
McCannel TA; McCannel CA
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):347-52. PubMed ID: 24721588
[TBL] [Abstract][Full Text] [Related]
39. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.
Shields CL; Naseripour M; Cater J; Shields JA; Demirci H; Youseff A; Freire J
Ophthalmology; 2002 Oct; 109(10):1838-49. PubMed ID: 12359604
[TBL] [Abstract][Full Text] [Related]
40. Changes in ultrasound findings in posterior uveal melanoma after Ruthenium 106 brachytherapy.
Kaiserman I; Anteby I; Chowers I; Blumenthal EZ; Kliers I; Pe'er J
Ophthalmology; 2002 Jun; 109(6):1137-41. PubMed ID: 12045056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
